Success Story: Looking Beyond the Cancer Diagnosis, NIW Approval for an Internal Medicine Physician Researcher
Client’s Testimonial:
“The process of working with Chen was thorough and detailed. They carefully analysed my first petition’s RFE and denial and drafted a second petition with additional modifications, which helped me secure approval. They have done a really good job with documentation wherein I did not have to worry about the nitty-gritty details.”
On March 6th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Physician in the Field of Internal Medicine (Approval Notice).
General Field: Internal Medicine
Position at the Time of Case Filing: Physician
Country of Origin: India
State of Residence at the Time of Filing: Arkansas
Approval Notice Date: March 6th, 2026
Processing Time: 1 month, 6 days (Premium Processing Requested)
Case Summary:
In oncology, the hardest cases are often not defined by cancer alone. They are shaped by everything surrounding it: diabetes, cardiovascular disease, obesity, treatment tolerance, access to care, and whether a patient can realistically participate in a trial at all. That clinical reality was central to this NIW approval.
The proposed endeavor centered on generating practice-changing evidence about how common chronic conditions influence cancer outcomes, treatment tolerability, and trial viability. North America Immigration Law Group (Chen Immigration Law Associates) presented this work as nationally important because it addressed a persistent weakness in cancer care: many patients treated in real-world settings do not resemble the idealized populations often reflected in research, yet their comorbidities directly shape survival, safety, and treatment decisions.
The filing showed that this research agenda was already grounded in concrete questions with broad relevance to the U.S. healthcare system. The petitioner planned to study factors contributing to excess radiation use in breast cancer patients and disparities affecting patients treated in rural and urban settings. Additionally, her work examined the clinical features that increase the risk of septic shock and death in patients with chronic myeloid leukemia. Framed together, these projects showed a physician researcher focused on where evidence can improve care most directly: at the point where cancer medicine meets complexity, access, and unequal outcomes. As one recommender put it, “Her focused research is crucial to the United States as it enables targeted resource allocation to address specific weaknesses within the US healthcare system.”
We documented 12 peer-reviewed journal articles, 41 abstracts, 1 preprint, 1 first-authored book chapter, at least 40 peer reviews, and 1,492 citations. Her work appeared in leading journals. The filing also showed that later researchers had relied on her work across cardiovascular epidemiology, rare cancers, zoonotic infection, hematologic disorders, and oncology-related toxicities, with one article ranking among the top 0.01% most-cited Clinical Medicine papers for its publication year.
We were proud to help secure this NIW approval for a physician-researcher whose work strengthens U.S. public health by asking a question that modern cancer care can no longer afford to ignore: what happens when the patient’s other illnesses are treated as central, rather than secondary, to the cancer story.